Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Table 1
Clinical characteristics. Different population variables of each study group are enlisted; none of them were statistically different between groups.
Clinical characteristics
Placebo
EZE/SIMV
ROSUV
Gender (M/F)†, (%)
7/17 (29/71)
10/15 (40/60)
12/13 (48/52)
Age (years)
54.7 ± 9.6
55.0 ± 12.0
54.0 ± 10.5
Weight (kg)
73.7 ± 11.4
75.4 ± 13.9
76.9 ± 18.7
Height (mt)
1.59 ± 0.09
1.60 ± 0.10
1.62 ± 0.13
Body mass index (kg/m2)
29.3 ± 4.3
29.4 ± 4.1
29.0 ± 4.7
DM type 2 duration (years)†
10.5 ± 8.3
10.2 ± 6.6
12.1 ± 8.3
Systolic blood pressure (mmHg)
142 ± 25
144 ± 25
135 ± 17
Diastolic blood pressure (mmHg)
84 ± 11
81 ± 10
81 ± 7
Smoking (Y/N)†, (%)
9/15 (38/62)
8/17 (32/68)
12/13 (48/52)
Concomitant drugs, (%)†
NSAID
1 (4)
2 (8)
2 (8)
Angiotensin Converter Enzyme Inhibitor
3 (13)
3 (13)
2 (8)
Angiotensin Receptor Blocker
2 (8)
1 (4)
Calcium antagonist
2 (8)
Aspirin
1 (4)
1 (4)
Proton Pump Inhibitors
2 (8)
2 (8)
Benzodiazepine
1 (4)
Diuretics
1 (4)
3 (13)
DM type 2 treatment, (%)
Insulin
1 (4.2)
2 (8.0)
4 (16.0)
Metformin
5 (20.8)
5 (20.0)
3 (12.0)
Glyburide
15 (62.5)
1 (4.0)
11 (44.0)
Metformin/glyburide
1 (4.2)
13 (52.0)
2 (8.0)
Metformin/insulin
2 (8.3)
2 (8.0)
3 (12.0)
Metformin/glyburide/insulin
2 (8.0)
2 (8.0)
Other combinations
Mean ± SD unless specified different. = NS Kruskal-Wallis, = NS. DM, diabetes mellitus; NSAID, nonsteroid anti-inflammatory drug.
